News|Videos|December 8, 2023

RSV Roundtable: What Clinicians are Witnessing in Terms of RSV Incidence

Last year’s historic RSV season left many wondering if this was going to become a recurring trend. Physicians weigh in on what they are seeing at their institutions in terms of infection rates.

We want to welcome you to the first episode from our respiratory syncytial virus (RSV) roundtable series, which is a collaborative effort that includes Contemporary Pediatrics, Contagion, and Contemporary OB/GYN. This series looks to discuss several topics around the virus, and it includes subjects such as incidence rates, preventative vaccines and immunizations, and how the introduction of these new prophylactic modalities can curb infections.

Our panel of clinicians includes:

  • Robert H. Hopkins Jr., MD: medical director, National Foundation for Infectious Diseases; professor of Internal Medicine and Pediatrics; chief, Division of General Internal Medicine, University of Arkansas for Medical Sciences
  • William Muller, MD, PhD: attending physician, Infectious Diseases; Ted Emerson Miller research scholar; professor of Pediatrics (Infectious Diseases), Northwestern University Feinberg School of Medicine; scientific director, Clinical and Community Trials, Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children’s Hospital
  • Sallie Permar, MD, PhD: Nancy C. Paduano professor and chair, Department of Pediatrics, Weill Cornell Medicine; pediatrician-in-chief, New York-Presbyterian/Weill Cornell Medical Center
  • Laura Riley, MD: chair, Department of Obstetrics and Gynecology, Weill Cornell Medicine; obstetrician and gynecologist-in-chief, New York-Presbyterian/Weill Cornell Medical Center
  • Neil Silverman, MD: professor, obstetrics and gynecology, David Geffen School of Medicine, UCLA; director, Maternal-Fetal Medicine Fellowship Program

This 5-part series that will be posted every Friday over the coming weeks. In today’s episode, clinicians discuss what they are seeing in terms of RSV incidence rates at their institutions compared to last year’s historic RSV season.

The RSV Roundtable video series is part of our larger special coverage project, RSV: A New Era in Prevention. Check out our library of articles and videos here from the project.


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.